Clinical trials: Alzheimer Disease, Late Onset
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer Disease, Late Onset Alzheimer Disease
Alzheimer's Disease Genetics Study
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD).
- Conditions
- Alzheimer Disease, Late Onset Alzheimer Disease, Dementia
- Trial name
- NCRAD (NCT00064870)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Indiana University
Mild Cognitive Impairment, Alzheimer Disease, Late Onset
Multimodal Assesment of Alzheimer Patients
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia
- Trial name
- MultiAD (NCT06448403)
- Testing
- MRI Scanning, 64-channel EEG, Polysomnography
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Dementia, Alzheimer Disease, Late Onset
Reducing Risk of Dementia Through Deprescribing
A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.
- Trial name
- R2D2 (NCT04270474)
- Testing
- Deprescribing of target anticholinergics, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 344 people
- Sponsor
- Indiana University
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years.
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change
- Trial name
- ALPS (NCT05138848)
- Testing
- Time in Bed Restriction, Sleep Schedule
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alzheimer Dementia, Late Onset Alzheimer Disease
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- REGEN-BRAIN© (NCT04838301)
- Testing
- Allopregnanolone
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Arizona
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer Disease, Alzheimer Disease, Early Onset
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Disease (Incl Subtypes)
- Trial name
- NCT05655195
- Testing
- GENUS device (Active Settings)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts Institute of Technology
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset
China Cognition and Aging Study
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and…
- Conditions
- Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
- Trial name
- COAST (NCT03653156)
- Where
- 65 sites in China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Late Onset, Cognitive Impairment
Effects of Personalized Music Listening in Advanced Alzheimer's
Recent functional imaging studies have facilitated a better understanding of the neuroplasticity mechanisms underlying the strong and multifaceted effects of music on brain development.
- Trial name
- NCT06765434
- Testing
- Music ( Dmitri Shostakovich's Jazz Waltz Suite), Music( Personalized music)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Okan University
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Alzheimer Disease, Alzheimer Disease, Late Onset
Transcranial Electromagnetic Treatment Against Alzheimer's Disease
This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT.
- Trial name
- NCT03927040
- Testing
- MemorEM 1000
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Alzheimer Disease, Late Onset
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
The goal of this clinical trial is to test whether vaccination with the BCG vaccine may improve the blood level of a biomarker of Alzheimer's disease (AD) in participants who are cognitively- and functionally- intact elderly…
- Trial name
- BCG-AD (NCT06078891)
- Testing
- BCG vaccine
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tamir Ben-Hur
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset
Genetic Studies in Familial Dementia
The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups.
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Trial name
- NCT04680013
- Where
- United States
- Volunteers
- 4,884 people, healthy volunteers welcome
- Sponsor
- University of Miami
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers
To establish the diagnostic and prognostic models that could help the preclinical identification of subjects at higher risk of clinical progression to mild cognitive impairment and dementia based on combined features of baseline…
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Subjective Cognitive Decline
- Trial name
- NCT06561906
- Testing
- Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Late Onset Alzheimer Disease
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline.
- Trial name
- NCT01222351
- Testing
- BAY 94-9172 (Florbetaben)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- New York State Psychiatric Institute
Late Onset Epilepsy, Alzheimer Disease
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET
Etiology and cognitive prognosis in late onset epilepsy differ from young adults epilepsy. At the epilepsy onset, this is crucial to detect potential curative/treatable brain disorders.
- Trial name
- EPITEP (NCT05831371)
- Testing
- TEP FDG
- Where
- France
- Volunteers
- 87 people
- Sponsor
- Central Hospital, Nancy, France